Most active Nasdaq-traded stocks
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:15PM CDT
Gilead announced encouraging results from two phase II studies and a compassionate access study on Sovaldi.
JPMorgan's Earnings Disaster Drops the Dow 100 Points
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 11, 1:38PM CDT
Earnings season has swung around hard on the market today, as the Dow Jones Industrial Average tumbled 130 points as of 2:30 p.m. EDT following some ugly numbers from one of America's top big banks. All but a handful of blue-chip stocks are in...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Fri Apr 11, 12:58PM CDT
Gilead Sciences (GILD) shares are up 3.9% to $67.98 in trading on Friday following Texas health board reconsideration
Midday Glance: Biotechnology companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Drying Stimulus Tap Is Sore Spot for Tech Stocks
at The Street - Fri Apr 11, 12:50PM CDT
The drying stimulus tap rather than stretched valuations has been the trigger for recent selling in tech and biotech shares, some managers argue, claiming this makes another tech sector crash unlikely.
Encouraging Data from Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 10:30AM CDT
Bristol-Myers announced positive data on its HCV cocktail treatment from a late stage study.
Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Stock Market News for April 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 9:06AM CDT
Benchmarks ended in the red zone yesterday, once again dragged down by declines in momentum and bio-tech stocks
Merck Shouts "Me, Too!" But Will It Matter?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 11, 8:30AM CDT
Merck has rolled out impressive phase 2 data that shows that it too has a very compelling hepatitis C regimen that may eliminate the use of side-effect laden Peginterferon and ribavirin -- the standard of care just a few short years ago. But...
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.
Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead Sciences
George Budwell, The Motley Fool - Motley Fool - Fri Apr 11, 7:57AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Enanta Pharmaceuticals and Gilead Sciences AbbVie and Enanta presented additional data from two late-stage studies dubbed SAPPHIRE-I and...
Gilead's Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Business Wire - Fri Apr 11, 12:02AM CDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. These data are being presented this week at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) in London.
Why Alexion Pharmaceuticals, Gilead Sciences, and Monster Beverage Corporation Are Today’s 3 Worst S
John Divine, The Motley Fool - Motley Fool - Thu Apr 10, 7:02PM CDT
After about seven out of every 10 stocks added ground yesterday, I opened my evening article with a simple sentence: "It was tough ," I said, "to lose money in the stock market today." Nothing could be further from the truth on Thursday, when the ...
Stocks Fall In Higher Volume; Alexion, Gilead Drop 7%
at Investor's Business Daily - Thu Apr 10, 4:05PM CDT
The major averages erased two days of gains Thursday as the tech-heavy Nasdaq recorded its biggest single-day decline since November 2011. The Nasdaq plunged 3.1%, led by former leaders in the software, solar-energy and biotech industries. The S&P...